Jean-SÃ©bastien Hulot

List of Publications by Year
in descending order

238 papers	20,769 citations	13827 67 h-index	10708 138 g-index
258 all docs	258 docs citations	258 times ranked	23978 citing authors

#	Article	IF	Citations
1	2013 ESC guidelines on the management of stable coronary artery disease. European Heart Journal, 2013, 34, 2949-3003.	1.0	3,915
2	Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI. JAMA - Journal of the American Medical Association, 2010, 304, 1821.	3.8	980
3	Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet, The, 2009, 373, 309-317.	6.3	864
4	Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood, 2006, 108, 2244-2247.	0.6	854
5	Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update. Clinical Pharmacology and Therapeutics, 2013, 94, 317-323.	2.3	795
6	Heart Rate and Cardiac Rhythm Relationships With Bisoprolol Benefit in Chronic Heart Failure in CIBIS II Trial. Circulation, 2001, 103, 1428-1433.	1.6	461
7	Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel Therapy. Clinical Pharmacology and Therapeutics, 2011, 90, 328-332.	2.3	422
8	Natural History and Risk Stratification of Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. Circulation, 2004, 110, 1879-1884.	1.6	387
9	Cardiovascular Risk in Clopidogrel-Treated Patients According to Cytochrome P450 2C19*2 Loss-of-Function Allele or Proton Pump Inhibitor Coadministration. Journal of the American College of Cardiology, 2010, 56, 134-143.	1.2	348
10	Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial. Lancet, The, 2010, 376, 1476-1484.	6.3	330
11	Statin therapy is associated with lower prevalence of gut microbiota dysbiosis. Nature, 2020, 581, 310-315.	13.7	283
12	Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis and Rheumatism, 2006, 54, 3284-3290.	6.7	274
13	Feasibility and safety of ultrasound-aided thoracentesis in mechanically ventilated patients. Intensive Care Medicine, 1999, 25, 955-958.	3.9	270
14	Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the <scp>H</scp>eart <scp>F</scp>ailure <scp>A</scp>ssociation (<scp>HFA</scp>), the <scp>E</scp>uropean <scp>A</scp>ssociation of <scp>C</scp>ardiovascular <scp>I</scp>maging (<scp>EACVI</scp>) and the <scp>Cardioâ€Oncology C</scp>ouncil of the <scp>E</scp>uropean <scp>S</scp>ociety of <scp>C</scp>ardiology (<scp>ESC</scp>). European Journal of Heart Failure, 2020, 22, 1504-1524.	2.9	234
15	Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. Lancet Respiratory Medicine,the, 2021, 9, 295-304.	5.2	232
16	Association betweenABCC2Gene Haplotypes and Tenofovirâ€Induced Proximal Tubulopathy. Journal of Infectious Diseases, 2006, 194, 1481-1491.	1.9	230
17	A PDGFRÎ±-Mediated Switch toward CD9high Adipocyte Progenitors Controls Obesity-Induced Adipose Tissue Fibrosis. Cell Metabolism, 2017, 25, 673-685.	7.2	195
18	The continuous heart failure spectrum: moving beyond an ejection fraction classification. European Heart Journal, 2019, 40, 2155-2163.	1.0	195

#	Article	IF	Citations
19	Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the <scp>Cardioâ€Oncology Study Group</scp> of the <scp>Heart Failure Association</scp> and the <scp>Cardioâ€Oncology Council of the European Society of Cardiology</scp>. European Journal of Heart Failure, 2020, 22, 1966-1983.	2.9	184
20	Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. Nephrology Dialysis Transplantation, 2005, 20, 743-746.	0.4	182
21	Clinical, Angiographic, and Genetic Factors Associated With Early Coronary Stent Thrombosis. JAMA - Journal of the American Medical Association, 2011, 306, 1765-74.	3.8	179
22	Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2007, 66, 821-824.	0.5	176
23	Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Associationâ€"European Society of Cardiology. European Heart Journal, 2018, 39, 4243-4254.	1.0	171
24	Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis. European Heart Journal, 2007, 28, 457-462.	1.0	168
25	Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study). Annals of the Rheumatic Diseases, 2013, 72, 1786-1792.	0.5	160
26	Correction of human phospholamban R14del mutation associated with cardiomyopathy using targeted nucleases and combination therapy. Nature Communications, 2015, 6, 6955.	5.8	155
27	Renal safety of tenofovir in HIV treatment-experienced patients. Aids, 2004, 18, 1074-1076.	1.0	153
28	Advancing functional engineered cardiac tissues toward a preclinical model of human myocardium. FASEB Journal, 2014, 28, 644-654.	0.2	148
29	Genetic Variants of the Î±-Synuclein Gene SNCA Are Associated with Multiple System Atrophy. PLoS ONE, 2009, 4, e7114.	1.1	144
30	Critical Role for Stromal Interaction Molecule 1 in Cardiac Hypertrophy. Circulation, 2011, 124, 796-805.	1.6	144
31	The CLIPMERGE PGx Program: Clinical Implementation of Personalized Medicine Through Electronic Health Records and Genomicsâ€"Pharmacogenomics. Clinical Pharmacology and Therapeutics, 2013, 94, 214-217.	2.3	144
32	PharmGKB summary. Pharmacogenetics and Genomics, 2012, 22, 159-165.	0.7	141
33	Small Molecule-Mediated Directed Differentiation of Human Embryonic Stem Cells Toward Ventricular Cardiomyocytes. Stem Cells Translational Medicine, 2014, 3, 18-31.	1.6	141
34	Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: Two double-blind, randomized, placebo-controlled studies. Kidney International, 2004, 66, 1153-1158.	2.6	138
35	Differential Effects of Lipid-Lowering Therapies on Stroke Prevention. Archives of Internal Medicine, 2003, 163, 669.	4.3	137
36	High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study. European Heart Journal, 2012, 33, 1241-1249.	1.0	127

#	Article	IF	Citations
37	A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination. Pharmacogenetics and Genomics, 2005, 15, 277-285.	0.7	125
38	Heart conduction disorders related to antimalarials toxicity: an analysis of electrocardiograms in 85 patients treated with hydroxychloroquine for connective tissue diseases. Rheumatology, 2007, 46, 808-810.	0.9	124
39	High Doses of Clopidogrel to Overcome Genetic Resistance. JACC: Cardiovascular Interventions, 2011, 4, 392-402.	1.1	118
40	Determinants of Hydroxychloroquine Blood Concentration Variations in Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2015, 67, 2176-2184.	2.9	118
41	Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects. Journal of Thrombosis and Haemostasis, 2007, 5, 2153-2155.	1.9	117
42	Can We Override Clopidogrel Resistance?. Circulation, 2009, 119, 2854-2857.	1.6	115
43	The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome. Journal of Thrombosis and Haemostasis, 2009, 7, 1409-1411.	1.9	114
44	CYP2C19 But Not PON1 Genetic Variants Influence Clopidogrel Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy in Postâ€“Myocardial Infarction Patients. Circulation: Cardiovascular Interventions, 2011, 4, 422-428.	1.4	110
45	Gene therapy for the treatment of heart failure: promise postponed. European Heart Journal, 2016, 37, 1651-1658.	1.0	110
46	Multidrug resistance-associated protein 4 regulates cAMP-dependent signaling pathways and controls human and rat SMC proliferation. Journal of Clinical Investigation, 2008, 118, 2747-2757.	3.9	105
47	Cardiomyopathy Related to Antimalarial Therapy with Illustrative Case Report. Cardiology, 2007, 107, 73-80.	0.6	103
48	Renal Tubular Drug Transporters. Nephron Physiology, 2006, 103, p97-p106.	1.5	102
49	Plasticity of Surface Structures and Î² ₂ -Adrenergic Receptor Localization in Failing Ventricular Cardiomyocytes During Recovery From Heart Failure. Circulation: Heart Failure, 2012, 5, 357-365.	1.6	102
50	Combinatorial, additive and dose-dependent drugâ€“microbiome associations. Nature, 2021, 600, 500-505.	13.7	102
51	Changes in Enoxaparin Pharmacokinetics During Pregnancy and Implications for Antithrombotic Therapeutic Strategy. Clinical Pharmacology and Therapeutics, 2008, 84, 370-377.	2.3	98
52	Comparison of echocardiography and plasma B-type natriuretic peptide for monitoring the response to treatment in acute heart failure. European Heart Journal, 2004, 25, 1788-1796.	1.0	97
53	Therapeutic Efficacy of AAV1.SERCA2a in Monocrotaline-Induced Pulmonary Arterial Hypertension. Circulation, 2013, 128, 512-523.	1.6	97
54	Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the <scp>Translational Research Committee</scp> of the <scp>Heart Failure Association</scp> (<scp>HFA</scp>) of the <scp>European Society of Cardiology</scp> (<scp>ESC</scp>). European Journal of Heart Failure, 2020, 22, 2272-2289.	2.9	92

#	Article	IF	Citations
55	ESC Working Group on Cellular Biology of the Heart: position paper for Cardiovascular Research: tissue engineering strategies combined with cell therapies for cardiac repair in ischaemic heart disease and heart failure. Cardiovascular Research, 2019, 115, 488-500.	1.8	90
56	Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes. Pharmacogenomics Journal, 2013, 13, 369-377.	0.9	87
57	Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil. Arthritis and Rheumatism, 2010, 62, 2047-2054.	6.7	85
58	Cardiac Stim1 Silencing Impairs Adaptive Hypertrophy and Promotes Heart Failure Through Inactivation of mTORC2/Akt Signaling. Circulation, 2016, 133, 1458-1471.	1.6	84
59	Inhibition of MRP4 prevents and reverses pulmonary hypertension in mice. Journal of Clinical Investigation, 2011, 121, 2888-2897.	3.9	83
60	RNA Interference Targeting STIM1 Suppresses Vascular Smooth Muscle Cell Proliferation and Neointima Formation in the Rat. Molecular Therapy, 2009, 17, 455-462.	3.7	82
61	The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: A randomized crossover clinical trial. Annals of Neurology, 2011, 69, 111-118.	2.8	82
62	Modeling susceptibility to drug-induced long QT with a panel of subject-specific induced pluripotent stem cells. ELife, 2017, 6, .	2.8	82
63	Long-Term Evolution of PrematureÂCoronary Artery Disease. Journal of the American College of Cardiology, 2019, 74, 1868-1878.	1.2	81
64	Antiplatelet and Anticoagulation Therapy for Acute Coronary Syndromes. Circulation Research, 2014, 114, 1929-1943.	2.0	79
65	Role of sarco/endoplasmic reticulum calcium content and calcium ATPase activity in the control of cell growth and proliferation. Pflugers Archiv European Journal of Physiology, 2009, 457, 673-685.	1.3	78
66	Obesity Doubles Mortality in Patients Hospitalized for Severe Acute Respiratory Syndrome Coronavirus 2 in Paris Hospitals, France: A Cohort Study on 5,795 Patients. Obesity, 2020, 28, 2282-2289.	1.5	76
67	Effect of intracoronary administration of <scp>AAV1</scp>/<scp>SERCA2a</scp> on ventricular remodelling in patients with advanced systolic heart failure: results from the <scp>AGENTâ€HF</scp> randomized phase 2 trial. European Journal of Heart Failure, 2017, 19, 1534-1541.	2.9	75
68	Cytotoxic CD8+ T cells promote granzyme B-dependent adverse post-ischemic cardiac remodeling. Nature Communications, 2021, 12, 1483.	5.8	73
69	Cyclic Nucleotide Compartmentalization: Contributions of Phosphodiesterases and ATP-Binding Cassette Transporters. Annual Review of Pharmacology and Toxicology, 2013, 53, 231-253.	4.2	71
70	Cardiac myocyteâ€“secreted cAMP exerts paracrine action via adenosine receptor activation. Journal of Clinical Investigation, 2014, 124, 5385-5397.	3.9	70
71	Androgenic Effects on Ventricular Repolarization. Circulation, 2019, 140, 1070-1080.	1.6	67
72	Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome. Clinical Pharmacology and Therapeutics, 2005, 77, 542-552.	2.3	66

#	Article	IF	Citations
73	Curative anticoagulation prevents endothelial lesion in COVIDâ€19 patients. Journal of Thrombosis and Haemostasis, 2020, 18, 2391-2399.	1.9	66
74	Stem Cell Factor Gene Transfer Promotes Cardiac Repair After Myocardial Infarction via In Situ Recruitment and Expansion of c-kit⁺Cells. Circulation Research, 2012, 111, 1434-1445.	2.0	63
75	Considerations for pre-clinical models and clinical trials of pluripotent stem cell-derived cardiomyocytes. Stem Cell Research and Therapy, 2014, 5, 1.	2.4	62
76	Regulation of cAMP homeostasis by the efflux protein MRP4 in cardiac myocytes. FASEB Journal, 2012, 26, 1009-1017.	0.2	61
77	Genomic correction of familial cardiomyopathy in human engineered cardiac tissues. European Heart Journal, 2016, 37, 3282-3284.	1.0	60
78	Downregulation of the calcium current in human right atrial myocytes from patients in sinus rhythm but with a high risk of atrial fibrillation. European Heart Journal, 2008, 29, 1190-1197.	1.0	58
79	Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects. Fundamental and Clinical Pharmacology, 2004, 18, 113-123.	1.0	57
80	Population pharmacokinetics of tacrolimus in full liver transplant patients: modelling of the post-operative clearance. European Journal of Clinical Pharmacology, 2005, 61, 409-416.	0.8	54
81	Lower vitamin D levels are associated with higher systemic lupus erythematosus activity, but not predictive of disease flare-up. Lupus Science and Medicine, 2014, 1, e000027.	1.1	54
82	Towards Precision Medicine With Human iPSCs for Cardiac Channelopathies. Circulation Research, 2019, 125, 653-658.	2.0	53
83	Influence of endogenous oestrogens on QT interval duration. European Heart Journal, 2003, 24, 1663-1667.	1.0	52
84	Effect of Renal Function on the Pharmacokinetics of Enoxaparin and Consequences on Dose Adjustment. Therapeutic Drug Monitoring, 2004, 26, 305-310.	1.0	52
85	Impaired platelet activation and cAMP homeostasis in MRP4-deficient mice. Blood, 2015, 126, 1823-1830.	0.6	51
86	Combination of B-type natriuretic peptide and peak oxygen consumption improves risk stratification in outpatients with chronic heart failure. American Heart Journal, 2003, 146, 729-735.	1.2	48
87	Pharmacokinetic Study of Mycophenolate Mofetil in Patients with Systemic Lupus Erythematosus and Design of Bayesian Estimator Using Limited Sampling Strategies. Clinical Pharmacokinetics, 2008, 47, 277-284.	1.6	48
88	Effectiveness of gene delivery systems for pluripotent and differentiated cells. Molecular Therapy - Methods and Clinical Development, 2015, 2, 14067.	1.8	47
89	Emerging Drug Classes and Their Potential Use in Hypertension. Hypertension, 2019, 74, 1075-1083.	1.3	46
90	MRP4 (ABCC4) as a potential pharmacologic target for cardiovascular disease. Pharmacological Research, 2016, 107, 381-389.	3.1	45

#	Article	IF	Citations
91	Functional Human Beige Adipocytes From Induced Pluripotent Stem Cells. Diabetes, 2017, 66, 1470-1478.	0.3	42
92	Population pharmacokinetic study of methotrexate in patients with lymphoid malignancy. Cancer Chemotherapy and Pharmacology, 2006, 58, 626-633.	1.1	41
93	Impact of ABCC2 polymorphisms on high-dose methotrexate pharmacokinetics in patients with lymphoid malignancy. Pharmacogenomics Journal, 2013, 13, 507-513.	0.9	40
94	CRISPR/Cas9 gene-editing strategies in cardiovascular cells. Cardiovascular Research, 2020, 116, 894-907.	1.8	40
95	Cardiac performance in patients hospitalized with COVIDâ€19: a 6Âmonth followâ€up study. ESC Heart Failure, 2021, 8, 2232-2239.	1.4	40
96	Epistatic Gene-Based Interaction Analyses for Glaucoma in eMERGE and NEIGHBOR Consortium. PLoS Genetics, 2016, 12, e1006186.	1.5	38
97	Effect of an increased clopidogrel maintenance dose or lansoprazole coâ€administration on the antiplatelet response to clopidogrel in CYP2C19â€genotyped healthy subjects. Journal of Thrombosis and Haemostasis, 2010, 8, 610-613.	1.9	36
98	Emergence of Orai3 activity during cardiac hypertrophy. Cardiovascular Research, 2015, 105, 248-259.	1.8	36
99	Antiplatelet drug interactions with proton pump inhibitors. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 175-189.	1.5	35
100	Sera Neutralizing Activities Against Severe Acute Respiratory Syndrome Coronavirus 2 and Multiple Variants 6 Months After Hospitalization for Coronavirus Disease 2019. Clinical Infectious Diseases, 2021, 73, e1337-e1344.	2.9	35
101	Resident PW1 ⁺ Progenitor Cells Participate in Vascular Remodeling During Pulmonary Arterial Hypertension. Circulation Research, 2016, 118, 822-833.	2.0	34
102	The lipodystrophic hotspot lamin A p.R482W mutation deregulates the mesodermal inducer T/Brachyury and early vascular differentiation gene networks. Human Molecular Genetics, 2018, 27, 1447-1459.	1.4	34
103	Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. Lancet Rheumatology, The, 2022, 4, e24-e32.	2.2	34
104	Potent human broadly SARS-CoV-2â€“neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2. Journal of Experimental Medicine, 2022, 219, .	4.2	34
105	Pharmacology and mechanisms of action of new oral anticoagulants. Fundamental and Clinical Pharmacology, 2015, 29, 10-20.	1.0	33
106	Assessment of signal quality measured with a smart 12â€lead ECG acquisition Tâ€shirt. Annals of Noninvasive Electrocardiology, 2020, 25, e12682.	0.5	33
107	Endothelial Cell Indoleamine 2, 3-Dioxygenase 1 Alters Cardiac Function After Myocardial Infarction Through Kynurenine. Circulation, 2021, 143, 566-580.	1.6	33
108	Simultaneous determination of rivaroxaban and dabigatran levels in human plasma by high-performance liquid chromatographyâ€“tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2014, 100, 230-235.	1.4	32

#	Article	IF	Citations
109	miR-322 regulates insulin signaling pathway and protects against metabolic syndrome-induced cardiac dysfunction in mice. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 611-621.	1.8	32
110	PON1 Q192R genetic variant and response to clopidogrel and prasugrel: pharmacokinetics, pharmacodynamics, and a meta-analysis of clinical outcomes. Journal of Thrombosis and Thrombolysis, 2016, 41, 374-383.	1.0	32
111	Dietary Assessment in the MetaCardis Study: Development and Relative Validity of an Online Food Frequency Questionnaire. Journal of the Academy of Nutrition and Dietetics, 2017, 117, 878-888.	0.4	32
112	COVID-19 in patients with cardiovascular diseases. Archives of Cardiovascular Diseases, 2020, 113, 225-226.	0.7	32
113	Sirolimus for treatment of patients with inclusion body myositis: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2b trial. Lancet Rheumatology, The, 2021, 3, e40-e48.	2.2	32
114	Beta-blocker treatment in heart failure. Fundamental and Clinical Pharmacology, 2001, 15, 95-109.	1.0	31
115	Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model analysis. British Journal of Clinical Pharmacology, 2005, 60, 364-373.	1.1	31
116	Hydroxychloroquine in systemic lupus erythematosus. Lancet, The, 2007, 369, 1257-1258.	6.3	31
117	Genetic and platelet function testing of antiplatelet therapy for percutaneous coronary intervention: the ARCTIC-GENE study. European Journal of Clinical Pharmacology, 2015, 71, 1315-1324.	0.8	31
118	Association Between Psychological Distress, Cognitive Complaints, and Neuropsychological Status After a Severe COVID-19 Episode: A Cross-Sectional Study. Frontiers in Psychiatry, 2021, 12, 725861.	1.3	31
119	Low-molecular-weight heparin vs. unfractionated heparin in percutaneous coronary intervention: A combined analysis. Catheterization and Cardiovascular Interventions, 2005, 65, 212-221.	0.7	30
120	Association of Oral Contraceptives With Drug-Induced QT Interval Prolongation in Healthy Nonmenopausal Women. JAMA Cardiology, 2018, 3, 877.	3.0	30
121	Animal models and animal-free innovations for cardiovascular research: current status and routes to be explored. Consensus document of the ESC Working Group on Myocardial Function and the ESC Working Group on Cellular Biology of the Heart. Cardiovascular Research, 2022, 118, 3016-3051.	1.8	30
122	Proteinuria and Clinical Outcomes in Hospitalized COVID-19 Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 514-521.	2.2	29
123	Outcome after revascularisation of acute myocardial infarction with cardiogenic shock on extracorporeal life support. EuroIntervention, 2018, 13, 2160-2168.	1.4	29
124	Do Anxiety and Depression Predict Persistent Physical Symptoms After a Severe COVID-19 Episode? A Prospective Study. Frontiers in Psychiatry, 2021, 12, 757685.	1.3	29
125	Corrected QT interval in anti-SSA-positive adults with connective tissue disease: Comment on the article by Lazzerini et al. Arthritis and Rheumatism, 2005, 52, 676-677.	6.7	28
126	Relationship between blood hydroxychloroquine and desethylchloroquine concentrations and cigarette smoking in treated patients with connective tissue diseases. Annals of the Rheumatic Diseases, 2007, 66, 1547-1548.	0.5	28

#	Article	IF	Citations
127	Anti-integrin Î±v therapy improves cardiac fibrosis after myocardial infarction by blunting cardiac PW1+ stromal cells. Scientific Reports, 2020, 10, 11404.	1.6	28
128	Routine CYP2C19 Genotyping to AdjustÂThienopyridine Treatment AfterÂPrimaryÂPCI for STEMI. JACC: Cardiovascular Interventions, 2020, 13, 621-630.	1.1	28
129	Fibrogenic Potential of PW1/Peg3 Expressing Cardiac Stem Cells. Journal of the American College of Cardiology, 2017, 70, 728-741.	1.2	27
130	COVID-19-related cardiac complications from clinical evidences to basic mechanisms: opinion paper of the ESC Working Group on Cellular Biology of the Heart. Cardiovascular Research, 2021, 117, 2148-2160.	1.8	26
131	Beta-blocker benefit according to severity of heart failure. European Journal of Heart Failure, 2003, 5, 281-289.	2.9	25
132	Platelet reactivity inhuman immunodeficiency virusinfected patients on dual antiplatelet therapy for an acute coronary syndrome: the EVERE₂ST-HIV study. European Heart Journal, 2017, 38, ehw583.	1.0	25
133	Personalized medicine for clopidogrel resistance?. Nature Reviews Cardiology, 2009, 6, 334-336.	6.1	24
134	Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end pointsâ€"Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC). American Heart Journal, 2018, 198, 152-159.	1.2	24
135	Differential Sarcomere and Electrophysiological Maturation of Human iPSC-Derived Cardiac Myocytes in Monolayer vs. Aggregation-Based Differentiation Protocols. International Journal of Molecular Sciences, 2017, 18, 1173.	1.8	23
136	Perivascular fibrosis and the microvasculature of the heart. Still hidden secrets of pathophysiology?. Vascular Pharmacology, 2018, 107, 78-83.	1.0	23
137	Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients. Fundamental and Clinical Pharmacology, 2006, 20, 321-330.	1.0	22
138	The pharmacogenetic control of antiplatelet response: candidate genes andCYP2C19. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 1599-1617.	1.5	22
139	Exome sequencing of extreme clopidogrel response phenotypes identifies B4GALT2 as a determinant of onâ€treatment platelet reactivity. Clinical Pharmacology and Therapeutics, 2016, 100, 287-294.	2.3	22
140	Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society of Cardiology (ESC). European Journal of Heart Failure, 2022, 24, 406-420.	2.9	22
141	Cardiomyocyte-Specific STIM1 (Stromal Interaction Molecule 1) Depletion in the Adult Heart Promotes the Development of Arrhythmogenic Discordant Alternans. Circulation: Arrhythmia and Electrophysiology, 2019, 12, e007382.	2.1	21
142	Urinary Elimination of Coproporphyrins Is Dependent onABCC2Polymorphisms and Represents a Potential Biomarker of MRP2 Activity in Humans. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-9.	3.0	20
143	Institutional profile: translational pharmacogenomics at the Icahn School of Medicine at Mount Sinai. Pharmacogenomics, 2017, 18, 1381-1386.	0.6	20
144	Visual lung damage CT score at hospital admission of COVID-19 patients and 30-day mortality. European Radiology, 2021, 31, 8354-8363.	2.3	20

#	Article	IF	Citations
145	Quality of life in systemic lupus erythematosus: description in a cohort of French patients and association with blood hydroxychloroquine levels. Lupus, 2016, 25, 735-740.	0.8	19
146	Potentiation of fluindione or warfarin by dexamethasone in multiple myeloma and AL amyloidosis. Joint Bone Spine, 2007, 74, 446-452.	0.8	18
147	Generating patient-specific induced pluripotent stem cells-derived cardiomyocytes for the treatment of cardiac diseases. Expert Opinion on Biological Therapy, 2015, 15, 1399-1409.	1.4	18
148	Hydroxychloroquine levels in patients with systemic lupus erythematosus: whole blood is preferable but serum levels also detect non-adherence. Arthritis Research and Therapy, 2020, 22, 223.	1.6	18
149	Vericiguat for the treatment of heart failure: mechanism of action and pharmacological properties compared with other emerging therapeutic options. Expert Opinion on Pharmacotherapy, 2021, 22, 1847-1855.	0.9	18
150	An Allele-Specific PCR System for Rapid Detection and Discrimination of the CYP2C19âˆ—4A, âˆ—4B, and âˆ—17 Alleles. Journal of Molecular Diagnostics, 2013, 15, 783-789.	1.2	17
151	Stent thrombosis: who's guilty?. European Heart Journal, 2009, 30, 2685-2688.	1.0	16
152	FXIII-A Leu34 genetic variant in premature coronary artery disease: A genotype â€“ phenotype case control study. Thrombosis and Haemostasis, 2011, 106, 511-520.	1.8	16
153	Pharmacogenetics of Clopidogrel. Current Pharmaceutical Design, 2012, 18, 5309-5327.	0.9	16
154	Urinary coproporphyrin <scp>I</scp>/(<scp>I</scp>â€‰+â€‰<scp>III</scp>) ratio as a surrogate for <scp>MRP2</scp> or other transporter activities involved in methotrexate clearance. British Journal of Clinical Pharmacology, 2014, 78, 329-342.	1.1	16
155	Aetiological classification and prognosis in patients with heart failure with preserved ejection fraction. ESC Heart Failure, 2022, 9, 519-530.	1.4	16
156	Clustering of Acute and Subacute Stent Thrombosis Related to the Introduction of Generic Clopidogrel. Journal of Cardiovascular Pharmacology and Therapeutics, 2014, 19, 201-208.	1.0	15
157	Cardiac inflammatory CD11b/c cells exert a protective role in hypertrophied cardiomyocyte by promoting TNFR2- and Orai3- dependent signaling. Scientific Reports, 2019, 9, 6047.	1.6	15
158	Omeprazole, pantoprazole, and CYP2C19 effects on clopidogrel pharmacokinetic-pharmacodynamic relationships in stable coronary artery disease patients. European Journal of Clinical Pharmacology, 2015, 71, 1059-1066.	0.8	14
159	Point-of-care genetic profiling and/or platelet function testing in acute coronary syndrome. Thrombosis and Haemostasis, 2016, 115, 382-391.	1.8	14
160	Nelfinavir and felodipine: a cytochrome P450 3A4?mediated drug interaction. Clinical Pharmacology and Therapeutics, 2004, 75, 362-363.	2.3	13
161	Multi-drug Resistance Protein 4 (MRP4/ABCC4) and cyclic nucleotides signaling pathways. Cell Cycle, 2009, 8, 959-964.	1.3	13
162	Genetic substudy of the PLATO trial. Lancet, The, 2011, 377, 637.	6.3	13

#	Article	IF	Citations
163	Complex Association of Sex Hormones on Left Ventricular Systolic Function: Insight into Sexual Dimorphism. Journal of the American Society of Echocardiography, 2018, 31, 231-240.e1.	1.2	13
164	GENomE wide analysis of sotalol-induced IKr inhibition during ventricular REPOLarization, â€œGENEREPOL studyâ€: Lack of common variants with large effect sizes. PLoS ONE, 2017, 12, e0181875.	1.1	13
165	Opioid-related genetic polymorphisms do not influence postoperative opioid requirement. European Journal of Anaesthesiology, 2018, 35, 496-504.	0.7	12
166	Reduced risk of cancer among lowâ€dose aspirin users: Data from French health care databases. Pharmacoepidemiology and Drug Safety, 2019, 28, 1258-1266.	0.9	12
167	Differential association between inflammatory cytokines and multiorgan dysfunction in COVID-19 patients with obesity. PLoS ONE, 2021, 16, e0252026.	1.1	12
168	Cytochrome P450 2C19 polymorphism and clopidogrel after MI â€“ Authors' reply. Lancet, The, 2009, 373, 1172-1173.	6.3	11
169	Thienopyridine-Associated Drug-Drug Interactions: Pharmacologic Mechanisms and Clinical Relevance. Current Cardiology Reports, 2011, 13, 451-458.	1.3	11
170	Sarcoplasmic reticulum and calcium cycling targeting by gene therapy. Gene Therapy, 2012, 19, 596-599.	2.3	11
171	Corrigendum to: '2013 ESC guidelines on the management of stable coronary artery disease'. European Heart Journal, 2014, 35, 2260-2261.	1.0	11
172	Modeling Cardiac Arrhythmias WithÂOrganoids. Journal of the American College of Cardiology, 2019, 73, 2325-2327.	1.2	11
173	Design and Validation of an Automated Process for the Expansion of Peripheral Blood-Derived CD34+ Cells for Clinical Use After Myocardial Infarction. Stem Cells Translational Medicine, 2019, 8, 822-832.	1.6	11
174	Association between coronary artery calcifications and 6-month mortality in hospitalized patients with COVID-19. Diagnostic and Interventional Imaging, 2021, 102, 717-725.	1.8	11
175	STIM1 and Orai in cardiac hypertrophy and vascular proliferative diseases Anne-Marie Lompre. Frontiers in Bioscience - Scholar, 2013, S5, 766-773.	0.8	11
176	Quantification of coproporphyrin isomers I and III in urine by HPLC and determination of their ratio for investigations of Multidrug Resistance Protein 2 (MRP2) function in humans. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2009, 877, 3893-3898.	1.2	10
177	Overexpression of Cyclic Adenosine Monophosphate Effluent Protein MRP4 Induces an Altered Response to Î²-Adrenergic Stimulation in the Senescent Rat Heart. Anesthesiology, 2015, 122, 334-342.	1.3	10
178	Cardiac Organoids to Model and Heal Heart Failure and Cardiomyopathies. Biomedicines, 2021, 9, 563.	1.4	10
179	Planning and monitoring of placebo-controlled survival trials: comparison of the triangular test with usual interim analyses methods. British Journal of Clinical Pharmacology, 2003, 55, 299-306.	1.1	9
180	Influence of methotrexate exposure on outcome in patients treated with MBVP chemotherapy for primary central nervous system lymphoma. British Journal of Clinical Pharmacology, 2010, 70, 367-375.	1.1	9

#	Article	IF	Citations
181	Impact of Inodilator Drugs on Echocardiographic Assessments of Left Ventricular Filling Pressure in Patients With Decompensated End-Stage Heart Failure*. Critical Care Medicine, 2014, 42, 2508-2517.	0.4	9
182	Modeling CVD in Human Pluripotent Cells by Genome Editing. Journal of the American College of Cardiology, 2014, 64, 460-462.	1.2	9
183	Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study. European Journal of Clinical Pharmacology, 2014, 70, 1049-1057.	0.8	9
184	Reg3Î² is associated with cardiac inflammation and provides prognostic information in patients with acute coronary syndrome. International Journal of Cardiology, 2018, 258, 7-13.	0.8	9
185	Therapeutic Drug Monitoring of Clozapine in a Hemodialysed Smoking Patient With Schizophrenia. Therapeutic Drug Monitoring, 2009, 31, 281-282.	1.0	8
186	Pharmacogenomics and personalized medicine: lost in translation?. Genome Medicine, 2010, 2, 13.	3.6	8
187	Development and Validation of a Rapid and Simple LC-MS/MS Method for Quantification of Vemurafenib in Human Plasma. Therapeutic Drug Monitoring, 2015, 37, 132-136.	1.0	8
188	Modulation of chromatin remodeling proteins SMYD1 and SMARCD1 promotes contractile function of human pluripotent stem cell-derived ventricular cardiomyocyte in 3D-engineered cardiac tissues. Scientific Reports, 2019, 9, 7502.	1.6	8
189	Late-Onset Giant Cell Myocarditis Due to Enterovirus During Treatment With Immune Checkpoint Inhibitors. JACC: CardioOncology, 2020, 2, 511-514.	1.7	8
190	Generation of iPSC line from MYH7 R403L mutation carrier with severe hypertrophic cardiomyopathy and isogenic CRISPR/Cas9 corrected control. Stem Cell Research, 2021, 52, 102245.	0.3	8
191	Ventricular Tachycardia in Arrhythmogenic Right Ventricular Cardiomyopathies. , 2004, , 588-600.		8
192	Multi-drug resistance protein 4 (MRP4/ABCC4) and cyclic nucleotides signaling pathways. Cell Cycle, 2009, 8, 962-3.	1.3	8
193	Clopidogrel and CYP2C19 Testing: Ready for Clinical Prime Time?. Clinical Chemistry, 2012, 58, 154-157.	1.5	7
194	Modeling of Amiodarone Effect on Heart Rate Control in Critically Ill Patients with Atrial Tachyarrhythmias. Clinical Pharmacokinetics, 2016, 55, 991-1002.	1.6	7
195	Genetic substudy of the PLATO trial â€“ Authors' reply. Lancet, The, 2011, 377, 637-638.	6.3	6
196	Do we need a new P2Y12 receptor antagonist?. European Heart Journal, 2020, 41, 3141-3143.	1.0	6
197	HFpEF: Should We Consider DiabeticÂPatients Separately?. Journal of the American College of Cardiology, 2021, 77, 420-422.	1.2	6
198	Antiplatelet Therapy and Coronary Artery Bypass Graft Surgery. Journal of the American College of Cardiology, 2010, 56, 2003-2005.	1.2	5

#	Article	IF	Citations
199	Myocardial Delivery of Stromal Cell-Derived Factor 1 in Patients With Ischemic Heart Disease. Circulation Research, 2013, 112, 746-747.	2.0	5
200	Inhalable delivery of AAV-based MRP4/ABCC4 silencing RNA prevents monocrotaline-induced pulmonary hypertension. Molecular Therapy - Methods and Clinical Development, 2015, 2, 14065.	1.8	5
201	Impact of negative inotropic drugs on accuracy of diastolic stress echocardiography for evaluation of left ventricular filling pressure. Scientific Reports, 2017, 7, 9537.	1.6	5
202	Sequential nephron blockade with combined diuretics improves diastolic function in patients with resistant hypertension. ESC Heart Failure, 2020, 7, 2561-2571.	1.4	5
203	miRNA-Based Therapeutics forÂHeartÂFailure. Journal of the American College of Cardiology, 2020, 75, 1801-1803.	1.2	5
204	Immune Signature Linked to COVID-19 Severity: A SARS-Score for Personalized Medicine. Frontiers in Immunology, 2021, 12, 701273.	2.2	5
205	Intravenous Clopidogrel (MDCO-157) Compared with Oral Clopidogrel: The Randomized Cross-Over AMPHORE Study. American Journal of Cardiovascular Drugs, 2016, 16, 43-53.	1.0	4
206	Chronic use of reninâ€angiotensinâ€aldosterone system blockers and mortality in COVIDâ€19: A multicenter prospective cohort and literature review. Fundamental and Clinical Pharmacology, 2021, 35, 1141-1158.	1.0	4
207	Cardiometabolic Disorders and the Risk of Critical COVID-19 as Compared to Influenza Pneumonia. Journal of Clinical Medicine, 2021, 10, 4618.	1.0	4
208	Clinical implications of neuropharmacogenetics. Revue Neurologique, 2015, 171, 482-497.	0.6	3
209	Effectiveness of heart rate control on hemodynamics in critically ill patients with atrial tachyarrhythmias managed by amiodarone. Pharmacological Research, 2017, 122, 118-126.	3.1	3
210	Suppression of Hematopoiesis in Recurrent Myocardial Infarction. Journal of the American College of Cardiology, 2020, 75, 916-918.	1.2	3
211	Pulmonary Hypertension: Novel Pathways and Emerging Therapies Inhibitors of cGMP and cAMP Metabolism. Handbook of Experimental Pharmacology, 2013, , 513-529.	0.9	3
212	Wytyczne ESC dotyczÄ…ce postÄ™powania w stabilnej chorobie wieÅ„cowej w 2013 roku. Kardiologia Polska, 2013, 71, 243-318.	0.3	3
213	Hypoxia promotes a perinatal-like progenitor state in the adult murine epicardium. Scientific Reports, 2022, 12, .	1.6	3
214	DIFFERENTIAL EFFECTS OF LIPID-LOWERING THERAPIES ON STROKE PREVENTION. Evidence-Based Eye Care, 2003, 4, 148-149.	0.2	2
215	Reply to Ray and Cihlar. Journal of Infectious Diseases, 2007, 195, 1390-1391.	1.9	2
216	Preclinical animal models for testing iPSC/ESC-based heart therapy. Drug Discovery Today: Disease Models, 2012, 9, e229-e236.	1.2	2

#	Article	IF	Citations
217	Pulmonary Hypertension: Novel Pathways and Emerging Therapies Inhibitors of cGMP and cAMP Metabolism. Handbook of Experimental Pharmacology, 2013, 218, 513-529.	0.9	2
218	Influence of Genetic Variations on Levels of Inflammatory Markers of Healthy Subjects at Baseline and One Week after Clopidogrel Therapy; Results of a Preliminary Study. International Journal of Molecular Sciences, 2013, 14, 16402-16413.	1.8	1
219	Spontaneous renal CT-scan hyperdensity of an HIV-associated nephropathy. Nephrology Dialysis Transplantation, 2003, 18, 2678-2678.	0.4	0
220	Potentialisation deÂlaÂfluindione etÂdeÂlaÂwarfarine parÂlaÂdexamÃ©thasone dansÂleÂmyÃ©lome multiple etÂl'amylose AL. Revue Du Rhumatisme (Edition Francaise), 2007, 74, 845-851.	0.0	0
221	Comment Ã©viter les piÃ¨ges des essais de non-infÃ©rioritÃ© ?. JEUR/Journal EuropÃ©en Des Urgences, 2008, 21, 5-7.	0.0	0
222	DÃ©terminants gÃ©nÃ©tiques deÂlaÂrÃ©ponse auÂclopidogrel. Hematologie, 2009, 15, 113-116.	0.0	0
223	The Inhibition Of MRP4, A New Target In Pulmonary Arterial Hypertension, Prevents And Reverses Hypoxia-induced Pulmonary Hypertension In Mice. , 2010, , .		0
224	Blockbuster interactions: are they bad for the patient?. European Heart Journal, 2012, 33, 2121-2123.	1.0	0
225	RÃ©sistance au clopidogrel, tests gÃ©nÃ©tiques et tests fonctionnels. Archives of Cardiovascular Diseases Supplements, 2012, 4, 209-216.	0.0	0
226	Get Your Cell K.O. in the First Round. Circulation Research, 2017, 120, 1522-1523.	2.0	0
227	InÂVitro Adherence Defines Therapeutic Cardiac Mesenchymal Cell Subpopulation â^—. Journal of the American College of Cardiology, 2017, 69, 1839-1841.	1.2	0
228	2525 Development of human cell-based screening assays to detect subject-specific drug-response variability. Journal of Clinical and Translational Science, 2018, 2, 9-10.	0.3	0
229	CRISPRed Cardiomyocytes to Decrypt Variants of Uncertain Significance. Journal of the American College of Cardiology, 2018, 72, 76-78.	1.2	0
230	3444 Development of human engineered cardiac tissue (hECT)-based screening assay to explore cardiac contractile properties in response to pharmacological challenge with proarrhythmic drugs. Journal of Clinical and Translational Science, 2019, 3, 8-8.	0.3	0
231	Modeling Cardiomyopathies with iPSCs. Current Human Cell Research and Applications, 2019, , 73-95.	0.1	0
232	Reply. JACC: Cardiovascular Interventions, 2020, 13, 1495-1496.	1.1	0
233	When Natural Peptides Meet Artificial Intelligence to Improve Risk Prediction. Journal of the American College of Cardiology, 2021, 78, 1632-1634.	1.2	0
234	STIM1 silencing prevents pressureâ€overload induced cardiac hypertrophy in mice. FASEB Journal, 2012, 26, 137.7.	0.2	0

#	Article	IF	Citations
235	Comment amÃ©liorer l'adhÃ©sion au traitement du malade atteint de lupus Ã©rythÃ©mateux ?. , 2013, , 239-240.		0
236	TNFR2â€mediated Survival via Orai1â€3â€dependent Calcium Influx in Compensated Cardiac Hypertrophy. FASEB Journal, 2015, 29, LB486.	0.2	0
237	Induced pluripotent stem cells for modeling of cardiac arrhythmias. , 2022, , 247-273.		0
238	RÃ1e des intÃ©grines dans la fibrose cardiaque. Medecine/Sciences, 2022, 38, 438-444.	0.0	0